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Use of corticosteroids in the treatment of intesttinal obstruction from carcinomatosis perittonei (CP) is an established practice.1,2 The 
purported mechanism of action of steroids in relieving 
intestinal obstruction is the reduction in inflammat
tion of the intestinal wall and surrounding soft tissue, 
thereby facilitating peristalsis with improved motility. 
We recently published our observation of an incidence 
of 45% of functional adrenal insufficiency in 29 cont
secutive patients with intestinal obstruction secondary 
to CP admitted to our oncology inpatient service. Short 
corticotrophin stimulation testing was performed in 
this prospective cohort of patients.3,4 Patients with 
pretexisting causes for adrenal suppression such as stet
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BACKGROUND AND OBJECTIVES: the purpose of this study was to confirm our hypothesis that the develop-
ment of functional intestinal obstruction in carcinomatosis peritonei (cp) is related to cytokine-mediated inhibi-
tion of the akt pathway and to investigate the phenomenon of relative adrenal insufficiency in cp.
METHODS: human adrenocortical cells (nci-h295r) were treated with serum derived from eight cancer pa-
tients who had intestinal obstruction and functional adrenal insufficiency. serum from three normal healthy 
subjects and three who had cp but without intestinal obstruction or adrenal insufficiency were used as controls. 
the differential effects of serum on the treated cells were studied using Western blot analysis. cortisol produc-
tion of these treated cells was assayed with cortisol elisa kits. 
RESULTS: phosphorylation of akt at ser473 and ser308 in cells was significantly reduced when treated with 
serum from patients with intestinal obstruction but not controls. phosphorylation of pdK1 at ser241, mtor 
downstream targets like p70s6 at thr421/ser424 and thr389, and lastly 4ebp-1 at ser70 a downstream target 
of p70s6 was reduced by approximately 50%, 40%, and 70%, respectively. there was enhanced phosphoryla-
tion of eif4e an initiating factor in protein translation in cells treated with patient serum compared to controls. 
cortisol synthesis was stimulated upon treatment with patient serum but not with control serum.
CONCLUSION: inhibition of akt phosphorylation is a mechanism that could play a major role in the develop-
ment of intestinal obstruction in carcinomatosis peritonei. the identification of the mediating cytokines will lead 
to the development of cogent targeted therapeutic strategies.
roid/ketoconazole usage, radiotherapy to the abdomit
nal region encompassing the adrenals within the field, 
and known pituitary hypofunction were excluded in the 
comparative analysis of this prospective observational 
study. The group of patients with functional adrenal 
insufficiency was found to have a significantly longer 
duration of hospitalization for management of intestit
nal obstruction (mean duration 7.9 versus 4.0 days per 
month of survival) and a shorter overall survival comt
pared to the group with normal adrenal function (190 
days versus 111 days; hazard ratio was 1.7; 95% cont
fidence interval, 1.3t2.2). Based on the results of this 
observational study, we hypothesized that there may 
be increased production of a single cytokine or mult
original research report AkT pATHwAy inHibiTiOn in inTeSTinAl ObSTruCTiOn
Hematol Oncol Stem Cell Ther 1(2)     April 2008 hemoncstem.edmgr.com74
tiple cytokines leading to direct inhibition of intestinal 
smooth muscle activity and that corticosteroids are able 
to reverse the smooth muscle function inhibition. Based 
on our observation of 45% relative adrenal insufficiency 
in such a situation, we further hypothesized that adret
nal response represented by compensatory endogenous 
cortisol production may be insufficient to surmount this 
inhibition, therefore requiring the use of exogenous cort
ticosteroids in maintaining normal intestinal motility. 
The activation of the Akt pathway and its downstream 
target the 70tkDa ribosomal S6 kinase (p70S6 kinase) 
are implicated in the hyperplasia of human intestinal 
smooth muscle cells and maintenance of their physit
ological mass.5 Corticosteroids regulate the phosphatit
dylinositol 3tkinase (PI3K) signaling pathway via serum 
and glucocorticoidtregulated protein kinases (SGKs) 
with Akt as one of the effectors.6 Furthermore, recent 
evidence suggests an important role for nonttranscript
tional effects of glucocorticoid receptor in the vascular 
system. The nonttranscriptional actions of glucocortit
coid receptor involve the rapid activation of protein kit
nases, such as PI3K and Akt, leading to the activation of 
endothelial nitric oxide synthase.7,8 This novel pathway 
of steroid hormone action protects against ischemic int
jury by augmenting blood flow and decreasing vascular 
inflammation. Therefore, the Akt pathway was identit
fied as a potential key mechanism in the development 
of functional intestinal obstruction in CP. We sought to 
confirm our postulation with this followtup study. We 
treated cortisoltproducing human adrenocortical cells 
(NCItH295R) with serum derived from patients with 
intestinal obstruction from CP with biochemically cont
firmed adrenal insufficiency. Serum from both healthy 
subjects and patients with CP but without intestinal 
obstruction were used as controls. The aim was to study 
the differential effects of patient serum on the Akt patht
way compared to controls and to determine the effect of 
the patients’ serum on cortisol production. 
METHODS
Patient selection and controls
Patients who were admitted to our oncology inpatient 
service for management of intestinal obstruction from 
CP with adrenal insufficiency were eligible for this 
study. Written informed consent was obtained from all 
subjects prior to participation in this study. All patients 
had histological confirmation of primary gastrointestit
nal cancers. The diagnosis of peritoneal carcinomatosis 
was based on the computed tomography scan of the 
abdomen, or positive peritoneal fluid cytology, or intrat
operative finding. Exclusion criteria were mainly prior 
diagnosis of adrenal insufficiency, known hypothalamic 
or pituitary dysfunction, the presence of brain metastat
ses, previous cranial irradiation, and use of corticostet
roids and ketoconazole. The control serum was derived 
from healthy volunteers among the investigators who 
were without any present illness and from patients with 
CP but without intestinal obstruction. 
Corticotropin stimulation test and definition of 
adrenal insufficiency
Adrenal function was assessed using the short cosynt
tropin stimulation test. This test involved intravenous 
administration of 250 µg of cosyntropin with plasma 
cortisol levels measured at 0, 30, and 60 minutes after 
administration. The timing of sampling for the baseline 
cortisol level was random. All blood specimens were 
drawn from a pretinserted heparinized venous cannula 
with the aid of a tourniquet. Functional adrenal insuffit
ciency was defined as having a baseline random cortisol 
level of less than 400 nmol/L and/or a best incremental 
response to cosyntropin of less than 250 nmol/L from 
baseline level. This definition was similar to our previt
ous study based on current clinical guidelines.3,4
A 5 mL blood sample was collected from each 
healthy volunteer and patient. Blood was centrifuged at 
3000g for 10 minutes at room temperature to separate 
the plasma and collected plasma was stored at t800ºC 
until utilisation. 
Cell culture and treatment
NCItH295R pluripotent adrenocortical carcinoma 
cells were obtained from the American Type Culture 
Collection, Manassas, Virginia. They were maintained 
in a 1:1 mixture of Dulbecco’s modified Eagle’s medit
um and Ham’s F12 medium (DMEM/F12) medium 
(Gibco, Grand Island, NY) supplemented with 10% 
fetal bovine serum (growth medium). To study the eft
fects of serum derived from patients and controls, 
NCItH295R cells were plated at 2.5×106 cells per 100 
mm tissue culture dish. Cells were allowed to grow in 
the growth medium for 24 hours. They were washed 
once with serumtfree DMEM/F12 medium and then 
treated with DMEM/F12 medium containing either 
5% serum from healthy individuals as controls or 5% 
serum derived from patients for 24 hours. At the end 
of the experiment, conditioned medium (CM) and 
cells were collected. CM was centrifuged at 3000g for 
10 minutes at room temperature to remove the cell det
bris and stored at t800ºC until analysis. Experiments 
were repeated at least three times, and the data were 
expressed as the mean±SD of the quadruplicate of each 
group.
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Cortisol production assay
The amount of cortisol secreted into CM was measured 
using cortisol ELISA kits (IBLtHamburg GmbH, 
Hamburg, Germany) according to the protocol of the 
manufacturer. The sensitivity for cortisol ELISA kit was 
2.5 ng/mL. Intratassay variation and intertassay variat
tion were 5.6% and 6.5%, respectively. The absorbance 
at 450 nm was measured using an ELISA plate reader 
(Benchmark Plus microplate spectrophotometer, Biot
Rad, Hercules, California, USA). 
Western blot analysis
To examine the effects of serum derived from patients 
on the Akt/mTOR pathways, cells were treated as det
scribed above. To inhibit the PIt3 kinase/Akt pathway, 
NCItH295R cells were treated with serum derived 
from a normal individual (N2) in the absence and prest
ence of 10 µM of PIt3 kinase inhibitor, LY294002. 
Treated cells were lysed in a lysis buffer and 100 µg of 
total cell lysate was subjected to Western blot analysis 
as described in reference 9. Blots were incubated with 
antitmTOR, Aktt1 and antit4EtBP1 antibodies and 
phosphorylationtspecific antibodies against mTOR 
(Ser2448), p70S6 kinase (Thr421/Ser424), p70S6 
kinase (Thr389), and 4EtBP1 (Thr70) (Cell Signaling 
Technology, Beverly, MA, USA and 1:7500 horseradt
ish peroxidasetconjugated donkey antitmouse or antit
rabbit secondary antibody. All the primary antibodies 
were used at a final concentration of 1 µg/mL. Blots 
were then visualized with a chemiluminescent detect
tion system (Amersham, Pharmacia Biotech, Arlington 
Heights, IL, USA) as described by the manufacturer. 
Blots were blotted with antitαttubulin (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) to serve as 
control. 
Statistical analysis
The Fischer exact test was used to determine significance 
of differences in results between controls and study subt
jects. Data analysis was performed with the aid of stat
tistical software SPSS version 14.0 for Windows. 
RESULTS
Serum was obtained from eight patients with intestit
nal obstruction from CP with adrenal insufficiency. Of 
these eight patients, two had gastric carcinoma, four 
had colon carcinoma and one had pancreatic carcinot
ma. Control serum was from three patients with colon 
carcinoma with CP but without intestinal obstruction 
or adrenal insufficiency, and also from three healthy 
subjects among the investigators. Phosphorylation of 
Akt at Ser473 and Ser308 in cells treated with study 
serum derived from the eight patients was significantly 
reduced (Figure 1), while control serum demonstrated 
no inhibition. Inhibition of the Akt pathway was not 
homogenous; serum from two patients (P2 and P6 in 
Figures 1a and 1b) did not significantly inhibit phost
porylation at Ser308. Neither serum from patients 
nor controls affected mTOR and its phosphotform. 
Phosphorylated PDK1 (upstream positive regulator of 
mTOR) at Ser241 was reduced by approximately 50%. 
Phosphorylation of p70S6 at Thr421/Ser424 and 
Thr389 (downstream targets of mTOR) were reduced 
by approximately 40%. Phosphorylated 4EBPt1 at 
Ser70 (downstream target of p70S6) was decreased by 
approximately 70%, while eIF4E phosphorylation was 
enhanced. Study serum derived from five patients with 
intestinal obstruction enhanced cortisol production by 
NCItH295R cells. Control serum did not enhance cort
tisol production in the latter (Figure 2). Serum from 
patients who had CP but not intestinal obstruction 
was similar to control serum from healthy subjects, and 
did not inhibit phosphorylation of Akt at Ser473 and 
Ser308, nor inhibit phosphorylation of p70S6 kinase 
(Thr389) and 4EtBP1 (Thr70) (Figure 3). The results 
of the statistical analysis showing significant inhibition 
of phosphorylation of Ser473, Ser308, Thr421, and 
Thr70 by patient serum compared with control serum 
as summarized in Table 1. 
DISCUSSION
Intestinal obstruction secondary to peritoneal carcit
nomatosis is frequently not relieved by surgery. The 
Table 1. Statistical analysis.
 
 t df 
P value 
(2-tailed) 
Mean 
Difference 
95% Confidence Interval of the Difference
Lower Upper
Ser473 -3.031 10 .013 -22.2727 -38.6464 -5.8991
Ser308 -2.849 10 .017 -24.1818 -43.0925 -5.2711
THr421 -2.904 10 .016 -18.2727 -32.2944 -4.2511
THr70 -3.586 10 .005 -19.4545 -31.5410 -7.3681
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Figures 1ab. effects of serum derived from patients with peritoneal carcinomatosis and intestinal obstruction on the phosphorylation 
of mTOr, p70S6 kinase, and 4e-bp1 in nCi-H295r adrenal carcinoma cells. Cells were grown in the DMeM/F12 medium containing 
10% FbS for 24 h. They were washed once with serum free DMeM/F12 medium and then treated with DMeM/F12 medium containing 
either 5% serum from healthy individuals (n1, n2), n2 in the presence of 10 μM of pi-3 kinase inhibitor, ly294002 or 5% serum derived 
from patients (p1-p5) for 24 h. lysates from cells were subjected to western blot analysis described. The blots were incubated with 
the indicated antibodies. representative blots and changes in the expression of indicated proteins are shown. experiments were 
repeated at least three times with similar results (n denotes controls, p denotes patients).
Figure 2. effects of serum derived from patients with peritoneal carcinomatosis and 
intestinal obstruction on cortisol production by nCi-H295r adrenal carcinoma cells. 
Cells were grown in the DMeM/F12 medium containing 10% FbS for 24 h. They were 
washed once with serum free DMeM/F12 medium and then treated with DMeM/F12 
medium containing either 5% serum from healthy individuals (n1, n2), n2 in the 
presence of 10 μM of pi-3 kinase inhibitor, ly294002 or 5% serum derived from patients 
(p1-p5) for 24 h. Conditioned medium was assayed for cortisol production using cortisol 
eliSA kits as described. The amount of cortisol secretion was expressed in ng/ml per 
106 cells. Standard deviation is 62.2 ng/ml per 106 cells.
development of intestinal obstruction invariably leads 
to frequent and prolonged hospitalizations that hert
ald irreversible deterioration in the quality of life of 
the patient with gastrointestinal cancer. While a ventt
ing gastrostomy, nasogastric tube suction, or bypass 
may palliate symptoms from intestinal obstruction, the 
treatment of intestinal obstruction in such a context is 
frequently medical management. In most instances, the 
outcome of medical management in achieving durable 
palliation is far from satisfactory. Aggressive use of nart
cotics, anticholinergics, antiemetics, phenothiazines, 
butyrophenones, tricyclic antidepressants, corticostet
roids, and somatostatin analogs may palliate symptoms 
associated with intestinal obstruction.10,11 The disparity 
of actions of these drugs reflects the empiricism of curt
rent medical management of intestinal obstruction in 
CP. It is imperative that our understanding be enhanced 
by a rational and systematic research into the mechat
nisms leading to the development of this condition. 
Mammalian target of rapamycin (mTOR) functions as a 
serine/threonine kinase to regulate protein translation, 
cell cycle progression, and cellular function.12,13 mTOR 
is phosphorylated in response to stimuli that activate 
the PI 3K/Akt pathway and regulates protein translat
A B
600
500
400
300
200
100
0
le
ve
ls
 o
f c
or
tis
ol
 s
ec
re
tio
n 
(m
g/
10
5  c
el
ls
)
        n1              n2          n2+ly           p1               p2             p3              p4               p5
Subjects
original research reportAkT pATHwAy inHibiTiOn in inTeSTinAl ObSTruCTiOn
Hematol Oncol Stem Cell Ther 1(2)     April 2008 hemoncstem.edmgr.com 77
Figure 3. effects of serum derived from patients with peritoneal 
carcinomatosis but without intestinal obstruction on the 
phosphorylation of mTOr, p70S6 kinase, and 4e-bp1 in nCi-H295r 
adrenal carcinoma cells. Cells were grown in the DMeM/F12 
medium containing 10% FbS for 24 h. They were washed once with 
serum free DMeM/F12 medium and then treated with DMeM/F12 
medium containing either 5% serum from healthy individuals (n1, 
n2, n3), ly294002 or 5% serum derived from patients (C4-C6) for 
24 h. lysates from cells were subjected to western blot analysis 
described. blots were incubated with indicated antibodies. 
representative blots and changes in the expression of indicated 
proteins are shown. experiments were repeated at least three 
times with similar results.
Figure 4. effects of serum derived from patients with peritoneal carcinomatosis and intestinal obstruction on the levels of phospho-
Akt (Ser473) (SD=27%), phospho-Akt (Ser308) (SD=30%), phospho-p70S6 (Thr421/Ser424) (SD=25%), and phospho-4ebp-1 (Thr70) 
(SD=21%) expressed as percentage of controls.
100
75
50
25
0
ph
os
ph
or
yl
at
io
n 
le
ve
l a
s 
%
 o
f c
on
tro
l
              ser473                                             ser308                             thr421/ser424                                     thr70
Samples
n (control)
n + ly
C4
C5
C6
p1
p2
p3
p4
p5
p6
p7
p8
tion through phosphorylation of ribosomal S6 kinase 
(S6K), eukaryotic initiation factor 4E binding protein 
1 (4EtBP1) and p70S6 kinase (p70S6K). p70S6K dit
rectly phosphorylates the 40S ribosomal protein S6, 
which correlated with enhanced translation of trant
scripts with 5’tterminal oligopyrimidine (5’tTOP) set
quences that encode components of translational mat
chinery such as ribosomal proteins and elongation fact
tors.14,15 Multitsite phosphorylation of the translational 
repressor 4EtBP1 by mTOR resulted in its dissociation 
from eIF4E, facilitating the recruitment of other transt
lation initiation factors to form the eIF4E complex and 
initiate captdependent translation.15 The activation of 
Akt pathway and its downstream target the 70tkDa rit
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bosomal S6 kinase (p70S6 kinase) are implicated in the 
hyperplasia of human intestinal smooth muscle cells 
and maintenance of their physiological mass through 
activation of translation initiators.5 Our study finding 
of inhibition of phosphorylation of PDK1 at Ser241, 
p70S6 at Thr421/Ser424 and Thr389, and 4EBPt1 at 
Ser70 mediated by factors in the serum from patients 
with intestinal obstruction in CP confirms our hyt
pothesis that reduced myogenicity of intestinal smooth 
muscle through cytokinetmediated Akt pathway int
hibition is one of the underlying mechanisms leading 
to intestinal obstruction (Figure 4). It is not known 
whether these cytokines are produced by the tumors 
or are part of an immune response mounted against 
the cancer. Identification of the cytokines that mediate 
these inhibitions will allow the development of a rat
tional therapeutic strategy. It is improbable that these 
effects are mediated by a single cytokine in view of hett
erogeneous inhibition of the Akt pathway as evident 
by the fact that serum from two patients (P2 and P6 
in Figure 1a and 1b) did not significantly inhibit phost
porylation at Ser308. This strategy may entail reducing 
the production of these inhibitory cytokines, antagot
nizing the effect of these cytokines at the sites of patht
way inhibition, and lastly, reversing the inhibition that 
may be already present. Candidate cytokines include 
ILt22 and myostatin, a transforming growth factor b 
super family member.16,17 This is the subject of our curt
rent ongoing research effort. The reason for enhanced 
phosphorylation of initiation factor eIF4E is complex 
and probably related to decreased protein intake in int
testinal obstruction.18,19 Phosphorylation of eIF4E is 
likely independent of upstream events in the Akt patht
way. Reduced protein intake cannot, however, entirely 
account for the selective inhibition of phosphorylation 
of PDK1, p70S6 and 4EBPt1 found in our study. Our 
finding of increased cortisol production by the NCIt
H295R pluripotent adrenocortical carcinoma cells 
when treated with patient serum was unexpected. 
Whether this increase in cortisol production is medit
ated by the same cytokines inhibiting the Akt pathway 
remains unknown. Corticosteroids activate the PI3K/
Akt pathway and acutely increase the endothelial NO 
synthase (eNOS) activity through a rapid nontnuclear 
nonttranscriptional process.8 Increased NO will result 
in vasodilatation and counterintuitively also antitint
flammatory effects.15 Akt may in turn regulate cortit
costeroid synthesis via eNOS production through a 
negative feedback loop. Phosphorylation of eNOS at 
Ser1177 by Akt directly stimulates eNOS activity and 
NO production.21 NO is a soluble gas and has been 
shown, like molecular oxygen and CO, to bind directly 
to the heme region of a number of P450s and inhibit 
their activity. The key steps regulating the initiation of 
steroidogenesis (P450scc) and two important committ
ting steps to aldosterone (P450aldo) or cortisol/C19 
steroids (P450c17) are all enzymes that use multiple 
rounds of attack of the hemetoxygen complex on the 
steroid substrate. P450c17 is a target of NO inhibit
tion.22 Further studies that confirm NO inhibition of 
P450scc also show that NO donors can still inhibit the 
conversion of progesterone to aldosterone, suggesting 
another site of NO action, possibly P450aldo.23 To 
further complicate matters, the effects of VEGF on 
permeability24 and vascular tone25 are coupled to nit
tric oxide (NO) production. VEGF has been shown 
to induce the release of NO from vascular endothelial 
cells by increasing phosphorylation of endothelial nit
trictoxide synthase (eNOS).26 Further studies of Akt, 
NO functions in adrenocortical steroidogenesis will 
be helpful in clarifying our findings. But certainly, int
creased cortisol production in our clinical context does 
not equal adequate adrenal response in relation to the 
physiological stress experienced. Unfortunately, in vitro 
tests will never allow a dynamic functional response ast
sessment. Even if we identify the optimal test to detert
mine functional adrenal insufficiency in cancer, several 
factors complicate the diagnosis of functional adrenal 
insufficiency based on laboratory tests. Since the hight
est levels of cortisol are found in patients with the most 
severe illness, both high and low cortisol levels have 
been reported to be associated with poor prognosis. 
This was seen in our study in that all of those patients 
with cortisol levels of more than 1000 nmol/L and a 
subtoptimal response to corticotropin stimulation test 
survived less than a week.3 Therefore, a solitary rant
dom cortisol level without a corticotropin stimulation 
test is inadequate in the diagnosis of functional adret
nal insufficiency in an ill patient. Changes in levels of 
cortisoltbinding globulin further complicate matters. 
Fluctuations in tissue sensitivity to the physiological 
action of cortisol certainly render a standard diagnost
tic range of test results that is reproducible in different 
patients with varying degrees of illness implausible.
In conclusion, our data suggest that cytokinetmedit
ated inhibition of the Akt pathway leading to reduced 
myogenicity of the intestinal smooth muscles is a 
mechanism that could play a major role in the develt
opment of intestinal obstruction in patients with CP. 
Identification of the mediating cytokines will help to 
determine opportune strategies to adopt in prevent
tion and treatment of intestinal obstruction in CP. 
Clarification of the roles that Akt, NO, VEGF and 
corticosteroids play in the complex web linking adrenal 
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